



Infectious Disease Lab Screening and Testing

April 24, 2024

Dear Providers,

SilverSummit HealthPlan presents new clinical payment policies to provide payment protocols for Infectious Disease Primary and Preventive Care Lab Screenings and Lab Testing related to Infectious Diseases. In accordance with the Laboratory Payment Policy, all providers billing for infectious disease testing services will be required to adhere to the coding recommendation in the Concert Genetics portal (for Medicaid, Ambetter and Wellcare)

<p>Infectious Disease: Respiratory Lab Testing CG.CP.MP.01</p>	<p>This policy outlines criteria for Syndromic/Multiplex Respiratory Panels with 6 or More Targets, SARS-CoV-2, RSV, or Influenza A/B, OR Multiplex Respiratory Viral Panels with 5 or Fewer Targets, Bacterial Respiratory Infection/Pneumonia Panels, Influenza A and B Antibody Tests, Group A Streptococcus Pharyngitis Tests, Group A Streptococcus Pharyngitis Cultures, and Group A Streptococcus Antibody Tests.</p>
<p>Infectious Disease: Multi-System Lab Testing CG.CP.MP.02</p>	<p>This policy outlines the appropriate use of tests for pathogens that can cause multisystem symptoms and/or infections. Tests for pathogens that infect multiple body systems can be targeted to detect a specific pathogen(s) or non-targeted to broadly detect nucleic acid from any potential pathogen.</p>
<p>Infectious Disease: Dermatologic Testing CG.CP.MP.03</p>	<p>This policy outlines the appropriate use of Microscopy/Peroxidase Tests, Fungal Culture, and Culture-Independent Molecular Tests (NAAT/PCR) for Onychomycosis.</p>
<p>Infectious Disease: Gastroenterologic Lab Testing CG.CP.MP.04</p>	<p>This policy outlines appropriate use of multi-pathogen panels, as well as diagnostic assays targeted at Helicobacter pylori (H. pylori).</p>
<p>Infectious Disease Primary Care and Preventive Lab Screening CG.CP.MP.05</p>	<p>This policy outlines criteria for human papillomavirus (HPV), hepatitis C virus (HCV), and group B streptococcus (GBS).</p>
<p>Infectious Disease: Vector-Borne and Tropical Diseases Lab Testing CG.CP.MP.06</p>	<p>This policy outlines criteria for Lyme disease and Zika virus testing via serologic and molecular methods.</p>
<p>Infectious Disease: Genitourinary Lab Testing CG.CP.MP.07</p>	<p>This policy outlines criteria for Targeted Vaginitis/Vaginosis Pathogen Testing, Expanded Multiplex Vaginitis/Vaginosis Pathogen Panels, Urine Culture for Asymptomatic Bacteriuria, and Molecular/Multiplex UTI Panels.</p>

Thank you for your support and continued partnership on providing our members with access to high-quality health care at an affordable price.

Thank you,

SilverSummit Healthplan